Cargando…
BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer
BRAF mutated colon cancer presents with poor survival, and the treatment strategies are controversial. The tumor microenvironment, which plays a key role in tumorigenesis as well as responses to treatments, of this subtype is largely unknown. In the present study, we analyzed the differences of immu...
Autores principales: | Cen, Shuyi, Liu, Kun, Zheng, Yu, Shan, Jianzhen, Jing, Chao, Gao, Jiale, Pan, Hongming, Bai, Zhigang, Liu, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350390/ https://www.ncbi.nlm.nih.gov/pubmed/34381786 http://dx.doi.org/10.3389/fcell.2021.705060 |
Ejemplares similares
-
T-Box Transcription Factor 22 Is an Immune Microenvironment-Related Biomarker Associated With the BRAF(V600E) Mutation in Papillary Thyroid Carcinoma
por: Dong, Xubin, et al.
Publicado: (2020) -
Bioinformatics-based analysis reveals elevated CYTL1 as a potential therapeutic target for BRAF-mutated melanoma
por: Tao, Lei, et al.
Publicado: (2023) -
Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022) -
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014) -
Major Vault Protein (MVP) Associated With BRAF
(V600E) Mutation Is an Immune Microenvironment-Related Biomarker Promoting the Progression of Papillary Thyroid Cancer via MAPK/ERK and PI3K/AKT Pathways
por: Dong, Xubin, et al.
Publicado: (2022)